Given GSK-3β is the convergence between insulin signaling and cytoskeleton dynamics, it is logical to suggest that CRMP2 is a candidate gene for T2DM susceptibility as CRMP2-mediated cytoskeleton remodeling determines the mass of adipose reservoir which is associated with obesity and metabolic abnormalities. The gene discussed is DPYSL2; the disease is Obesity.